Navigation Links
Multiple myeloma patients experience high response rate with new 3-drug combination
Date:12/5/2009

NEW ORLEANSA new three-drug combination has shown in a phase 1/2 clinical trial that it is a "highly effective regimen" in the treatment of patients newly diagnosed with multiple myeloma, a cancer of white blood cells in bone marrow, say researchers from Dana-Farber Cancer Institute.

Partial responses or better were seen in all of the 66 patients treated with the drug combination in the multi-center study, with 74 percent having a "very good partial response rate" in the phase 2 population, reports Paul G. Richardson, MD, of Dana-Farber, who led the study. The rate of complete or "near complete" responses to the therapy was also encouraging at 54 percent.

Richardson will describe the results in an oral presentation at the American Society of Hematology's 51st annual meeting on Saturday, Dec. 5 (Abstract 1218, Ernest N. Morial Convention Center, Hall E, 5:30-7:30 pm CT).

The regimen, known as RVD, combined the drugs Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone, which previously were found to be highly effective in multiple myeloma patients who had relapsed or no longer responded to first-line therapies.

Fifteen of the 35 newly diagnosed patients in the open-label phase 2 portion of the study subsequently underwent autologous (using their own blood-forming stem cells) transplants, a standard treatment for multiple myeloma "and did very well," says Richardson.

For the entire group, after a median 19.3 months of follow up, the median time-to-progression (TTP) of the disease, progression-free survival (PFS), and overall survival (OS) had not yet been reached, according to the presentation. The estimated TTP and PFS at one year are 76 percent, and the estimated one-year overall survival is 100 percent, the results showed.

An estimated 20,580 new cases of multiple myeloma will be diagnosed in 2009, according to the American Cancer Society, and 10,580 patients will die from the disease.

Richardson says it was "particularly exciting" to observe that the high response rate was not affected by the specific genetic characteristics of the patients' disease. Patients with so-called "adverse cytogenetics" are at higher risk for treatment failure and death, but in the current study the drug combination worked as well for them as it did in patients with more favorable cytogenetic features.

The toxic side effects of the treatment were "manageable," Richard says. The main adverse effect was peripheral neuropathy (numbness or pain in the extremities), which typically cleared up after dosages were lowered and the treatment was completed.

"Our conclusion is that this is a highly effective regimen for newly diagnosed multiple myeloma patients," says Richardson. "The combination has now gone into large phase 3 clinical trials, and we think it has the potential to be a new standard of treatment in multiple myeloma."


'/>"/>

Contact: Teresa Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Timing of Multiple-Ligament Knee Surgery May Not Matter
2. Childbirth May Slow Progression of Multiple Sclerosis
3. Multiple Health Conditions Discovered During Free Clinic for Uninsured People in New Orleans
4. Patient Advocate Foundation Announces Additional Support for Co-Pay Relief Program Serving Multiple Myeloma Patients
5. Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy
6. Catheter-Delivered Valve May Help People With Heart Defects Avoid Multiple Surgeries
7. New IVF Guidelines Aim to Reduce Multiple Births
8. Gentle touch may aid multiple sclerosis patients
9. People with Multiple Sclerosis are Proactively Improving their Walking, Energy Level, Confidence and Quality of Life
10. Early Drug Treatment May Cut Multiple Sclerosis Risk
11. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. , ... tests, has received two prestigious recognitions that acknowledge the promise of its PWS ... Preora has been named a Top 100 Finalist for the 16th annual Chicago ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand that specializes in ... the athletic wear market with the launch of their FlipBelt Crops. , The new ... securely at their fingertips while at the gym, on the trail, or on-the-go. , ...
(Date:9/21/2017)... CO (PRWEB) , ... September 21, 2017 , ... ... Interview of the Month, Lewis and Clark College Emeritus Professor of Education Gregory ... Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... Collins ... System for clients that rely on safety and cleanliness. This unique flooring system ... Silver has been used for centuries for its antimicrobial properties. Unlike antibiotics, which ...
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added the ... of medical professionals working on a personal injury lien basis. Founded by Dr. Wayne ... these esteemed doctors’ vast experience with orthopedic injuries to patients in the Inland Empire. ...
Breaking Medicine News(10 mins):
(Date:9/1/2017)... PALMER, Mass. , Sept. 1, 2017 ... Complete HealthCare Solutions, Inc , highlights opportunities for growth ... Street Journal report that Marlin Equity is seeking a ... is an annual award-winning 22-year-old healthcare solutions Value Added ... market.  "As the ...
(Date:8/29/2017)... -- ivWatch, LLC, the leading provider of continuous monitoring devices for ... awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven ... ... early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based ...
(Date:8/25/2017)... ), an Irish medtech company, today announced that it has commenced working ... Bassetlaw, England . The collaboration sees the company,s ... national NHS Test Bed programme exploring new models of care. ... Innovation Zed ... accessory for disposable insulin pen users, automatically collects and records pen usage ...
Breaking Medicine Technology: